[DEBUG-WINDOW 처리영역 보기]
BRIC을 시작페이지로 회원가입    로그인
BRIC한국을 빛내는 사람들
배너1 스폰서배너광고 안내
오늘의 BRIC정보
트위터 페이스북
검색 뉴스레터 안내
좋은 연구문화 만들기
Bio일정 프리미엄(유료) 등록이란?
2017년 8월달 Bio일정을 확인하세요.
바이오 형광사진
실험의 달인들
Biojob 프리미엄(유료) 등록이란?
대메뉴안내: 한빛사
한빛사논문 추천논문 상위피인용논문 한빛사인터뷰 한빛사그이후
김광수 (Kwang-Soo Kim) 저자 이메일 보기
Harvard Medical School
조회 544  인쇄하기 주소복사 트위터 공유 페이스북 공유 
라이카코리아는 BRIC 후원기관입니다.
[Commentary]Toward neuroprotective treatments of Parkinson’s disease

Kwang-Soo Kima,b,1

Molecular Neurobiology Laboratory, Program in Neuroscience, Harvard Medical School, Boston, MA 02115;
bDepartment of Psychiatry, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478

Parkinson’s disease (PD) is, after Alzheimer’s disease, the second most-common neurodegenerative disorder affecting 1-2% of the global population over the age of 65 (1, 2). Aging being a primary risk factor for PD (3), its economic burden on our society in terms of medical care will escalate with our aging population. The major pathophysiological features of PD include selective and progressive degeneration of A9 midbrain dopaminergic (mDA) neurons in the substantia nigra and widespread accumulation of intraneuronal proteinaceous inclusions, called Lewy bodies, whose major component is misfolded α-synuclein. A9 DA neurons project to the dorsal striatum and form the nigrostriatal pathway, which controls voluntary movements. Degeneration of this pathway in PD patients results in decreased dopamine levels in the striatum, leading to clinical manifestations, such as resting tremor, rigidity, bradykinesia, and gait dysfunctions (1, 2). Since its introduction in the 1960s, dopamine replacement therapy through levodopa (l-dopa) and DA agonist administration remain the standard treatment for PD (4). Although this pharmacological treatment dramatically improves the quality of life of numerous PD patients, its efficacy wanes over time and the need for increased dosage eventually induces severe side effects, such as dyskinesia. Although there are alternative surgical treatments, such as deep brain stimulation (5), both forms of treatment are symptomatic and cannot stop or modify the disease progression. Therefore, there is a significant unmet need for the development of novel neuroprotective and disease-modifying therapeutics for PD. In PNAS, Spathis et al. (6) introduce a novel compound, BRF110, which is a unique Nurr1: retinoid X receptor-α (RXRα)-selective “agonist” that can prevent DA neurons’ demise and striatal DA denervation in vivo in several preclinical models of PD. Remarkably, this study shows that BRF110 is not only neuroprotective in sparing mDA neurons, but also upon a single administration led to significant …

1To whom correspondence may be addressed.

- 형식: Commentary
- 게재일: 2017년 03월 (BRIC 등록일 2017-03-31)
- 연구진: 국외연구진
  댓글 0
생화학분자생물학회 스폰서배너광고 안내
김광수 님 전체논문보기 >
고지윤 (한양대학교)
김덕중 (Harvard Medical School)
김도훈 (Harvard Medical School)
김천형 (서울대학교)
문지숙 (차의과학대학교, Harvard M...)
이미옥 (한국생명공학연구원)
이상훈 (한양대학교)
이용희 (한양대학교)
장미윤 (McLean Hospital/Harvard M...)
정상미 (McLean Hospital/Harvard M...)
차영 (McLean Hospital/Harvard Med...)
차혁진 (서강대학교)
한민준 (St. Jude Children’s Rese...)
한백수 (한국생명공학연구원, Harva...)
황동윤 (Harvard Medical School)
Google (by Kwang-Soo Kim)
Pubmed (by Kwang-Soo Kim)
AccuPower GreenStar RT-qPCR Master Mix
모집인원: 30명
모집기간: ~8/6
신청조건: BRIC 회원
평가자 혜택

- 참가자 전원 2만원 상품권
- 우수평가자  5명에게 3만원 상품권


제품평가자 모집중
프리미엄 Bio일정 Bio일정 프리미엄 안내
[8월 9일 수요일] 품질분석 시험방법 밸리데이션 (Validation of Analytical Procedures)
[8월 9일 수요일] 품질분석 시험방법 밸리데이션 (Validation of Analytical Procedures)
사전접수: ~2017.08.08
날짜: 2017.08.09
장소: 구로디지털단지 우림이비지센터2차 1406호 (2호선 구로디지털단지역 3번출구 도보 10분)
2017 부산대학교 의학전문대학원 의과학과 Open Lab
2017 부산대학교 의학전문대학원 의과학과 Open Lab
사전접수: ~2017.08.16
날짜: 2017.08.21
장소: 부산대학교 의학전문대학원(양산) 통합행정동 116호
이전페이지로 돌아가기 맨위로 가기

BRIC 홈    BRIC 소개    회원    검색    문의/FAQ    광고    후원
Copyright © BRIC. All rights reserved. Contact member@ibric.org